calcitriol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Vitamin D analogues/derivatives	466	32222-06-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rocaltrol calcitriol Dihydroxyvitamin D3 topitriol 1,25-dihydroxyvitamin D3	The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. Molecular weight: 416.65 Formula: C27H44O3 CLOGP: 6.04 LIPINSKI: 1 HAC: 3 HDO: 3 TPSA: 60.69 ALOGS: -4.80 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rocaltrol
calcitriol
Dihydroxyvitamin D3
topitriol
1,25-dihydroxyvitamin D3

The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.

Molecular weight: 416.65
Formula: C27H44O3
CLOGP: 6.04
LIPINSKI: 1
HAC: 3
HDO: 3
TPSA: 60.69
ALOGS: -4.80
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	mcg	O
1	mcg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	8 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	61 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.25 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.31 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	11 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 17, 1978	FDA	VALIDUS PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Recalled product	1068.23	11.15	216	25545	1187	63462074
Hypocalcaemia	581.27	11.15	275	25486	31438	63431823
Hypercalcaemia	492.75	11.15	237	25524	28085	63435176
Milk-alkali syndrome	251.51	11.15	60	25701	768	63462493
Calciphylaxis	209.29	11.15	69	25692	3003	63460258
Peritonitis bacterial	188.82	11.15	72	25689	4807	63458454
Blood calcium decreased	156.92	11.15	110	25651	26341	63436920
Tetany	140.55	11.15	46	25715	1955	63461306
Blood parathyroid hormone increased	129.05	11.15	48	25713	2990	63460271
Shunt stenosis	127.72	11.15	32	25729	508	63462753
Arteriovenous fistula site complication	114.39	11.15	29	25732	484	63462777
Blood calcium abnormal	109.03	11.15	34	25727	1234	63462027
Nephrocalcinosis	97.30	11.15	30	25731	1048	63462213
Nephrogenic systemic fibrosis	94.19	11.15	43	25718	4513	63458748
Shunt occlusion	93.05	11.15	26	25735	639	63462622
Peritonitis	89.49	11.15	66	25695	17088	63446173
Hypercalciuria	80.76	11.15	20	25741	302	63462959
Renal failure	80.28	11.15	159	25602	117493	63345768
Hypoparathyroidism	79.09	11.15	23	25738	655	63462606
Chronic kidney disease	74.49	11.15	92	25669	45306	63417955
Aplasia pure red cell	70.31	11.15	35	25726	4452	63458809
Blood calcium increased	70.13	11.15	45	25716	9305	63453956
Acute kidney injury	67.17	11.15	247	25514	263168	63200093
Rheumatoid arthritis	63.24	11.15	13	25748	253806	63209455
Renal impairment	62.18	11.15	121	25640	88234	63375027
Drug ineffective	61.10	11.15	219	25542	1044546	62418715
Drug intolerance	57	11.15	27	25734	308634	63154627
Treatment failure	54.37	11.15	8	25753	199035	63264226
Glossodynia	54.29	11.15	5	25756	178871	63284390
Systemic lupus erythematosus	53.51	11.15	10	25751	208908	63254353
Synovitis	52.26	11.15	7	25754	186911	63276350
Arthropathy	50.85	11.15	16	25745	234776	63228485
Peritoneal dialysis complication	50.81	11.15	19	25742	1201	63462060
Contraindicated product administered	50.52	11.15	13	25748	217635	63245626
Joint swelling	50.10	11.15	36	25725	327630	63135631
Kidney transplant rejection	48.89	11.15	27	25734	4244	63459017
Completed suicide	47.23	11.15	3	25758	145670	63317591
Hyperphosphataemia	45.79	11.15	21	25740	2227	63461034
Blood creatinine increased	45.27	11.15	106	25655	87738	63375523
Skin induration	44.26	11.15	23	25738	3200	63460061
Hyperparathyroidism tertiary	44.19	11.15	8	25753	21	63463240
Hyperparathyroidism secondary	43.97	11.15	18	25743	1449	63461812
Renal transplant	41.59	11.15	17	25744	1363	63461898
Drug hypersensitivity	41.49	11.15	241	25520	310446	63152815
Anaemia	40.74	11.15	230	25531	293200	63170061
Skin hypertrophy	40.37	11.15	22	25739	3369	63459892
Blood phosphorus increased	39.10	11.15	21	25740	3124	63460137
Brown tumour	38.94	11.15	8	25753	48	63463213
Infusion related reaction	38.80	11.15	26	25735	245495	63217766
Therapeutic product effect decreased	38.66	11.15	15	25746	193172	63270089
Hyperparathyroidism	35.99	11.15	19	25742	2730	63460531
Hepatic enzyme increased	35.37	11.15	19	25742	202309	63260952
Pericarditis	34.32	11.15	6	25755	131573	63331688
Alopecia	33.78	11.15	53	25708	337483	63125778
Hungry bone syndrome	33.13	11.15	8	25753	108	63463153
Hospitalisation	31.79	11.15	91	25670	84990	63378271
Acute myocardial infarction	30.28	11.15	50	25711	32074	63431187
Pulmonary renal syndrome	30.13	11.15	10	25751	444	63462817
Hypervitaminosis D	29.91	11.15	7	25754	82	63463179
Dialysis	29.16	11.15	28	25733	10399	63452862
Wound	29.02	11.15	15	25746	163248	63300013
Fungal peritonitis	28.63	11.15	10	25751	519	63462742
Septic shock	28.61	11.15	75	25686	66554	63396707
Skin tightness	28.06	11.15	19	25742	4297	63458964
Nephrolithiasis	27.71	11.15	56	25705	41928	63421333
Muscle spasms	27.60	11.15	131	25630	156019	63307242
Skin fibrosis	27.06	11.15	11	25750	869	63462392
Lower respiratory tract infection	26.92	11.15	10	25751	132297	63330964
Parathyroidectomy	26.64	11.15	8	25753	255	63463006
Sinusitis	26.25	11.15	32	25729	226621	63236640
Peritoneal dialysis	26.24	11.15	9	25752	442	63462819
Unresponsive to stimuli	25.85	11.15	48	25713	33768	63429493
Pain	25.54	11.15	186	25575	740442	62722819
Abdominal discomfort	25.40	11.15	58	25703	320827	63142434
Hypervolaemia	23.85	11.15	42	25719	28371	63434890
Paraesthesia oral	23.83	11.15	34	25727	19222	63444039
Product use issue	23.62	11.15	33	25728	220487	63242774
Metabolic alkalosis	23.62	11.15	15	25746	3046	63460215
Swelling	23.26	11.15	48	25713	275330	63187931
Arthralgia	23.20	11.15	136	25625	569574	62893687
Haemodialysis	23.10	11.15	23	25738	8924	63454337
Anti-erythropoietin antibody positive	23.08	11.15	8	25753	406	63462855
Calcinosis	22.87	11.15	13	25748	2159	63461102
Mental status changes	22.85	11.15	50	25711	39549	63423712
End stage renal disease	22.66	11.15	20	25741	6673	63456588
Pulse absent	22.18	11.15	18	25743	5356	63457905
Blood potassium increased	22.17	11.15	32	25729	18277	63444984
Parathyroid tumour benign	21.75	11.15	9	25752	744	63462517
Coagulation test abnormal	21.25	11.15	9	25752	789	63462472
Discomfort	21.16	11.15	22	25739	167352	63295909
Irritable bowel syndrome	20.96	11.15	4	25757	82408	63380853
Blood urea increased	20.87	11.15	38	25723	26341	63436920
Azotaemia	20.65	11.15	16	25745	4455	63458806
Impaired healing	20.44	11.15	8	25753	102534	63360727
Maternal exposure during pregnancy	19.75	11.15	37	25724	220025	63243236
Hyperparathyroidism primary	19.51	11.15	7	25754	393	63462868
Chronic kidney disease-mineral and bone disorder	18.97	11.15	5	25756	98	63463163
Diabetic foot	18.94	11.15	10	25751	1437	63461824
Rash	18.74	11.15	142	25619	560729	62902532
Hypoglycaemia	18.45	11.15	60	25701	60005	63403256
Intentional overdose	18.03	11.15	4	25757	74148	63389113
Hypersensitivity	17.86	11.15	60	25701	292625	63170636
Vascular parkinsonism	17.74	11.15	5	25756	127	63463134
Haemoglobin decreased	17.55	11.15	110	25651	145375	63317886
Polyhydramnios	17.20	11.15	11	25750	2260	63461001
Bone pain	17.16	11.15	55	25706	54586	63408675
Alveolar bone resorption	16.71	11.15	4	25757	52	63463209
Urinary tract infection	16.48	11.15	172	25589	264512	63198749
Fibromyalgia	16.48	11.15	6	25755	80414	63382847
Arrhythmia	16.43	11.15	43	25718	38097	63425164
Daydreaming	16.39	11.15	6	25755	357	63462904
Parathyroid disorder	16.10	11.15	7	25754	654	63462607
Electrolyte imbalance	15.98	11.15	29	25732	20047	63443214
Hypertension	15.78	11.15	178	25583	279125	63184136
Urine calcium increased	15.76	11.15	4	25757	67	63463194
Sepsis	15.59	11.15	111	25650	153012	63310249
Blister	15.37	11.15	18	25743	129796	63333465
Arteriovenous fistula thrombosis	15.06	11.15	5	25756	222	63463039
Musculoskeletal stiffness	14.89	11.15	33	25728	184585	63278676
Papillary thyroid cancer	14.83	11.15	10	25751	2246	63461015
Anti-neutrophil cytoplasmic antibody positive vasculitis	14.77	11.15	11	25750	2888	63460373
Cerebral infarction	14.74	11.15	31	25730	23862	63439399
Renal tubular necrosis	14.73	11.15	21	25740	11857	63451404
Product supply issue	14.54	11.15	9	25752	1746	63461515
Blood magnesium decreased	14.45	11.15	22	25739	13176	63450085
Fatigue	14.39	11.15	264	25497	887764	62575497
Vomiting	14.35	11.15	312	25449	559305	62903956
Staphylococcal infection	14.32	11.15	43	25718	41213	63422048
Gastrointestinal haemorrhage	14.25	11.15	68	25693	81108	63382153
Diffuse alopecia	13.92	11.15	7	25754	909	63462352
Drug abuse	13.90	11.15	6	25755	72512	63390749
Hypocalcaemic seizure	13.85	11.15	3	25758	24	63463237
Nephrotic syndrome	13.78	11.15	14	25747	5562	63457699
Simple partial seizures	13.74	11.15	6	25755	567	63462694
Asthenia	13.66	11.15	225	25536	383379	63079882
Nephropathy toxic	13.63	11.15	18	25743	9461	63453800
Loss of personal independence in daily activities	13.20	11.15	12	25749	97278	63365983
Bone metabolism biochemical marker increased	13.16	11.15	3	25758	31	63463230
Cardiac arrest	13.10	11.15	73	25688	92472	63370789
Nasopharyngitis	12.99	11.15	56	25705	254201	63209060
Encapsulating peritoneal sclerosis	12.95	11.15	5	25756	345	63462916
Psoriatic arthropathy	12.77	11.15	11	25750	91509	63371752
Paraesthesia	12.76	11.15	108	25653	156858	63306403
Peripheral swelling	12.74	11.15	60	25701	265882	63197379
Cardio-respiratory arrest	12.61	11.15	53	25708	59906	63403355
Urosepsis	12.57	11.15	25	25736	18499	63444762
Gingival hypertrophy	12.42	11.15	8	25753	1663	63461598
Iron deficiency	12.41	11.15	15	25746	7215	63456046
Dehydration	12.41	11.15	116	25645	173238	63290023
Sleep disorder	12.39	11.15	9	25752	81557	63381704
Suicidal ideation	12.22	11.15	5	25756	62416	63400845
Cerebral calcification	12.20	11.15	4	25757	171	63463090
International normalised ratio increased	12.18	11.15	44	25717	46381	63416880
Hypotension	12.06	11.15	166	25595	272438	63190823
Suicide attempt	11.74	11.15	5	25756	60913	63402348
Osteoarthritis	11.52	11.15	13	25748	95330	63367931
Ultrafiltration failure	11.43	11.15	4	25757	209	63463052
Incision site impaired healing	11.37	11.15	4	25757	212	63463049
Haemodialysis complication	11.34	11.15	4	25757	214	63463047
Bloody peritoneal effluent	11.23	11.15	3	25758	62	63463199
Knee arthroplasty	11.18	11.15	4	25757	54202	63409059

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	335.00	13.41	148	23868	8453	34924462
Appendicitis	288.76	13.41	159	23857	14648	34918267
Cardiogenic shock	210.11	13.41	162	23854	26456	34906459
Blood phosphorus increased	196.22	13.41	99	23917	7622	34925293
Peritonitis bacterial	193.30	13.41	91	23925	6019	34926896
Stress	183.24	13.41	158	23858	30189	34902726
Ascites	142.99	13.41	168	23848	46403	34886512
Shunt stenosis	141.65	13.41	42	23974	740	34932175
Hypercalcaemia	137.22	13.41	101	23915	15367	34917548
Abdominal distension	133.52	13.41	182	23834	58310	34874605
Ventricular fibrillation	131.46	13.41	116	23900	22838	34910077
Shunt occlusion	128.77	13.41	40	23976	830	34932085
Hypocalcaemia	125.81	13.41	116	23900	24173	34908742
Blood parathyroid hormone increased	125.61	13.41	45	23971	1469	34931446
Arteriovenous fistula site complication	124.89	13.41	34	23982	433	34932482
Multiple organ dysfunction syndrome	105.72	13.41	189	23827	76377	34856538
Drug hypersensitivity	105.13	13.41	194	23822	80335	34852580
General physical health deterioration	94.16	13.41	245	23771	128024	34804891
Nephrocalcinosis	88.42	13.41	28	23988	620	34932295
Abdominal pain	80.41	13.41	271	23745	163347	34769568
Blood uric acid increased	79	13.41	60	23956	9564	34923351
Recalled product	77.80	13.41	22	23994	325	34932590
Vomiting	76.24	13.41	354	23662	247267	34685648
Dry mouth	72.02	13.41	96	23920	30069	34902846
Hyponatraemia	71.22	13.41	168	23848	82523	34850392
Constipation	70.03	13.41	230	23786	136752	34796163
Nephrogenic systemic fibrosis	69.85	13.41	40	23976	3965	34928950
Sepsis	69.09	13.41	261	23755	166300	34766615
Peritoneal dialysis complication	68.41	13.41	30	23986	1679	34931236
Hypercalciuria	66.79	13.41	19	23997	287	34932628
Drug ineffective	66.46	13.41	134	23882	456617	34476298
Peritonitis	65.69	13.41	68	23948	16297	34916618
Hyperphosphataemia	63.49	13.41	39	23977	4398	34928517
Aplasia pure red cell	63.47	13.41	44	23972	6088	34926827
Chronic kidney disease	54.61	13.41	100	23916	41110	34891805
Mean platelet volume increased	52.58	13.41	18	23998	512	34932403
Hyperparathyroidism secondary	51.58	13.41	24	23992	1544	34931371
Hyperparathyroidism	50.67	13.41	22	23994	1202	34931713
Hypervolaemia	49.00	13.41	64	23952	19645	34913270
Myasthenia gravis	45.67	13.41	38	23978	6902	34926013
Zoonotic bacterial infection	45.13	13.41	10	24006	49	34932866
Hypophosphataemia	42.79	13.41	45	23971	10981	34921934
Hospitalisation	41.97	13.41	109	23907	56793	34876122
Nephrectomy	41.94	13.41	17	23999	781	34932134
Mycobacterium marinum infection	41.21	13.41	13	24003	284	34932631
Ventricular hyperkinesia	40.87	13.41	12	24004	204	34932711
Mycobacterium test positive	40.58	13.41	14	24002	408	34932507
Hypochromasia	40.22	13.41	13	24003	308	34932607
Calciphylaxis	39.96	13.41	18	23998	1074	34931841
Febrile neutropenia	38.74	13.41	23	23993	136826	34796089
Right atrial enlargement	38.53	13.41	12	24004	251	34932664
Nausea	38.01	13.41	378	23638	339530	34593385
Lung diffusion test decreased	35.30	13.41	14	24002	607	34932308
Mitral valve thickening	33.77	13.41	12	24004	382	34932533
Blood calcium decreased	33.63	13.41	38	23978	10046	34922869
Tendon calcification	32.41	13.41	8	24008	67	34932848
Analgesic therapy	31.97	13.41	15	24001	983	34931932
Completed suicide	31.49	13.41	14	24002	98154	34834761
Drug therapy	30.06	13.41	15	24001	1126	34931789
Blood creatinine increased	29.24	13.41	136	23880	94840	34838075
Calcinosis	29.14	13.41	13	24003	758	34932157
Carotid arteriosclerosis	28.30	13.41	17	23999	1841	34931074
Narrow anterior chamber angle	28.11	13.41	8	24008	121	34932794
Toxicity to various agents	27.13	13.41	61	23955	200301	34732614
Left ventricular enlargement	27.06	13.41	12	24004	690	34932225
Hypertensive heart disease	26.63	13.41	18	23998	2390	34930525
Skin induration	26.01	13.41	17	23999	2134	34930781
Sleep disorder therapy	25.64	13.41	13	24003	1010	34931905
Shunt infection	25.37	13.41	7	24009	94	34932821
Hypophosphatasia	25.26	13.41	6	24010	42	34932873
Proteinuria	24.38	13.41	45	23971	18597	34914318
Anti-erythropoietin antibody positive	24.27	13.41	12	24004	883	34932032
Left atrial enlargement	24.15	13.41	12	24004	893	34932022
Blood urea increased	23.23	13.41	59	23957	30305	34902610
Peripheral arterial occlusive disease	22.83	13.41	24	23992	5850	34927065
Chronic kidney disease-mineral and bone disorder	22.66	13.41	9	24007	392	34932523
Blood cholesterol increased	22.48	13.41	46	23970	20497	34912418
Haemoglobin decreased	22.48	13.41	151	23865	120621	34812294
Skin fibrosis	22.44	13.41	12	24004	1040	34931875
Bronchiolitis	22.17	13.41	18	23998	3158	34929757
Hungry bone syndrome	21.85	13.41	6	24010	79	34932836
Granuloma	21.80	13.41	18	23998	3233	34929682
Haemodialysis	21.37	13.41	31	23985	10495	34922420
Blood iron decreased	21.18	13.41	22	23994	5291	34927624
Iron deficiency	20.94	13.41	22	23994	5359	34927556
Renal transplant	20.87	13.41	14	24002	1835	34931080
Skin tightness	20.62	13.41	15	24001	2238	34930677
Arthralgia	20.47	13.41	55	23961	169986	34762929
Hypervitaminosis D	20.43	13.41	4	24012	9	34932906
Myasthenic syndrome	20.22	13.41	9	24007	522	34932393
Joint contracture	20.13	13.41	14	24002	1947	34930968
Interstitial lung disease	19.87	13.41	10	24006	65272	34867643
Blood chloride increased	19.42	13.41	16	24000	2865	34930050
Renal transplant failure	19.16	13.41	11	24005	1095	34931820
Potentiating drug interaction	18.75	13.41	20	23996	4957	34927958
Skin hypertrophy	18.56	13.41	15	24001	2614	34930301
Haematocrit decreased	18.14	13.41	56	23960	32160	34900755
Obstruction	18.12	13.41	15	24001	2704	34930211
Suicidal ideation	18.09	13.41	3	24013	40385	34892530
Interstitial granulomatous dermatitis	17.35	13.41	6	24010	176	34932739
Lymphocyte count decreased	17.35	13.41	44	23972	22578	34910337
Incorrect route of product administration	17.15	13.41	34	23982	14811	34918104
Mucosal inflammation	17.01	13.41	3	24013	38619	34894296
Porphyria acute	16.90	13.41	7	24009	340	34932575
Hepatic cyst infection	16.72	13.41	4	24012	29	34932886
Parathyroidectomy	16.56	13.41	5	24011	94	34932821
Therapeutic product effect incomplete	16.53	13.41	7	24009	50534	34882381
Myopathy	16.52	13.41	29	23987	11525	34921390
Upper respiratory tract infection	16.38	13.41	55	23961	33004	34899911
Blood calcium increased	16.37	13.41	16	24000	3578	34929337
Electrocardiogram T wave inversion	16.33	13.41	13	24003	2218	34930697
Milk-alkali syndrome	16.08	13.41	8	24008	597	34932318
Lens dislocation	15.95	13.41	5	24011	107	34932808
Intentional product use issue	15.62	13.41	11	24005	59805	34873110
Blood erythropoietin decreased	15.56	13.41	3	24013	6	34932909
Blood 1,25-dihydroxycholecalciferol decreased	15.56	13.41	3	24013	6	34932909
Insomnia	15.42	13.41	30	23986	103877	34829038
Red cell distribution width increased	15.39	13.41	20	23996	6103	34926812
Disease progression	15.35	13.41	32	23984	108045	34824870
Intestinal prolapse	15.03	13.41	5	24011	130	34932785
Fibrosis	14.87	13.41	13	24003	2523	34930392
Arteriovenous fistula occlusion	14.71	13.41	5	24011	139	34932776
Anaemia	14.55	13.41	233	23783	233102	34699813
Incorrect dose administered	14.26	13.41	5	24011	40510	34892405
Reticulocyte count abnormal	14.24	13.41	3	24013	11	34932904
Bone deformity	14.15	13.41	4	24012	59	34932856
Renal impairment	14.04	13.41	112	23904	94401	34838514
Bacterial infection	13.94	13.41	34	23982	17029	34915886
Neutrophil count decreased	13.87	13.41	9	24007	51095	34881820
Zoonosis	13.84	13.41	3	24013	13	34932902
Serum ferritin increased	13.80	13.41	19	23997	6127	34926788
Azotaemia	13.72	13.41	17	23999	4950	34927965
Kidney transplant rejection	13.67	13.41	21	23995	7476	34925439
End stage renal disease	13.67	13.41	23	23993	8838	34924077
Blood alkaline phosphatase decreased	13.67	13.41	8	24008	826	34932089
Pyelonephritis	13.64	13.41	19	23997	6196	34926719
Diastolic dysfunction	13.61	13.41	19	23997	6208	34926707
Malignant neoplasm progression	13.43	13.41	25	23991	88021	34844894

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypercalcaemia	469.46	11.35	276	41184	38154	79664774
Recalled product	389.11	11.35	92	41368	862	79702066
Hypocalcaemia	379.66	11.35	266	41194	49658	79653270
Appendicolith	371.97	11.35	147	41313	8404	79694524
Peritonitis bacterial	352.60	11.35	146	41314	9421	79693507
Appendicitis	276.83	11.35	158	41302	20636	79682292
Shunt stenosis	269.27	11.35	74	41386	1317	79701611
Milk-alkali syndrome	231.33	11.35	66	41394	1354	79701574
Arteriovenous fistula site complication	230.90	11.35	61	41399	928	79702000
Blood phosphorus increased	230.50	11.35	111	41349	10236	79692692
Shunt occlusion	205.59	11.35	61	41399	1443	79701485
Calciphylaxis	204.02	11.35	76	41384	3694	79699234
Cardiogenic shock	201.28	11.35	170	41290	41744	79661184
Blood parathyroid hormone increased	159.58	11.35	62	41398	3383	79699545
Peritonitis	141.39	11.35	117	41343	27919	79675009
Drug hypersensitivity	140.05	11.35	406	41054	298510	79404418
Ventricular fibrillation	130.16	11.35	118	41342	31808	79671120
Ascites	128.95	11.35	177	41283	75385	79627543
Nephrogenic systemic fibrosis	116.14	11.35	59	41401	6101	79696827
Stress	116.03	11.35	173	41287	79439	79623489
Nephrocalcinosis	114.32	11.35	39	41421	1463	79701465
Multiple organ dysfunction syndrome	110.90	11.35	213	41247	120033	79582895
Abdominal distension	106.75	11.35	209	41251	119441	79583487
Sepsis	101.17	11.35	339	41121	269089	79433839
Drug ineffective	101.14	11.35	262	41198	1080651	78622277
Chronic kidney disease	95.31	11.35	143	41317	66011	79636917
Blood calcium decreased	92.97	11.35	98	41362	31721	79671207
Peritoneal dialysis complication	90.37	11.35	37	41423	2317	79700611
Hyperphosphataemia	89.02	11.35	50	41410	6326	79696602
Blood uric acid increased	87.34	11.35	65	41395	13295	79689633
Aplasia pure red cell	87.25	11.35	53	41407	7757	79695171
Hospitalisation	85.73	11.35	166	41294	94070	79608858
Completed suicide	76.64	11.35	17	41443	245750	79457178
Hyperparathyroidism secondary	73.08	11.35	33	41427	2627	79700301
Hyponatraemia	70.46	11.35	228	41232	177620	79525308
Rheumatoid arthritis	70.09	11.35	12	41448	208458	79494470
Tetany	69.15	11.35	32	41428	2696	79700232
General physical health deterioration	68.47	11.35	304	41156	274934	79427994
Hypercalciuria	65.61	11.35	20	41440	520	79702408
Vomiting	64.10	11.35	576	40884	665252	79037676
Drug abuse	62.78	11.35	6	41454	162685	79540243
Hyperparathyroidism	58.23	11.35	30	41430	3194	79699734
Joint swelling	57.33	11.35	40	41420	288606	79414322
Synovitis	57.01	11.35	6	41454	150728	79552200
Skin induration	56.52	11.35	33	41427	4492	79698436
Abdominal pain	55.83	11.35	370	41090	389199	79313729
Renal impairment	55.17	11.35	194	41266	157589	79545339
Blood creatinine increased	54.52	11.35	191	41269	154866	79548062
Renal failure	51.48	11.35	224	41236	200744	79502184
Hypervolaemia	51.38	11.35	85	41375	42605	79660323
Constipation	50.10	11.35	284	41176	282766	79420162
Hungry bone syndrome	49.62	11.35	13	41447	191	79702737
Blood calcium increased	49.52	11.35	42	41418	10358	79692570
Hypophosphataemia	47.23	11.35	55	41405	19858	79683070
Renal transplant	46.86	11.35	24	41436	2523	79700405
Skin hypertrophy	46.38	11.35	30	41430	4898	79698030
Zoonotic bacterial infection	46.34	11.35	10	41450	59	79702869
Arthralgia	46.33	11.35	148	41312	571655	79131273
Treatment failure	45.31	11.35	16	41444	170470	79532458
Blood calcium abnormal	43.86	11.35	19	41441	1370	79701558
Myasthenia gravis	43.48	11.35	39	41421	10360	79692568
Toxicity to various agents	43.28	11.35	97	41363	421443	79281485
Contraindicated product administered	43.23	11.35	14	41446	157524	79545404
Arthropathy	43.16	11.35	19	41441	177092	79525836
Hyperparathyroidism tertiary	43.08	11.35	8	41452	18	79702910
Mycobacterium marinum infection	42.95	11.35	14	41446	455	79702473
Calcinosis	42.69	11.35	22	41438	2343	79700585
Brown tumour	42.17	11.35	9	41451	50	79702878
Kidney transplant rejection	42.00	11.35	38	41422	10208	79692720
Infusion related reaction	41.75	11.35	35	41425	230202	79472726
Mean platelet volume increased	40.94	11.35	17	41443	1103	79701825
Intentional overdose	40.63	11.35	4	41456	105956	79596972
Ventricular hyperkinesia	40.31	11.35	12	41448	287	79702641
Alopecia	39.75	11.35	37	41423	231318	79471610
Hand deformity	39.65	11.35	4	41456	103915	79599013
Mycobacterium test positive	39.49	11.35	13	41447	436	79702492
Hepatic enzyme increased	39.40	11.35	23	41437	182587	79520341
Parathyroidectomy	39.34	11.35	11	41449	209	79702719
Skin fibrosis	39.01	11.35	18	41442	1506	79701422
Blood urea increased	38.45	11.35	81	41379	48709	79654219
Haemodialysis	37.88	11.35	47	41413	18121	79684807
Sinusitis	37.61	11.35	28	41432	195473	79507455
Chronic kidney disease-mineral and bone disorder	37.12	11.35	13	41447	528	79702400
Right atrial enlargement	37.02	11.35	12	41448	383	79702545
Glossodynia	36.88	11.35	5	41455	103332	79599596
Systemic lupus erythematosus	36.51	11.35	9	41451	121140	79581788
Skin tightness	36.39	11.35	27	41433	5495	79697433
Mitral valve thickening	36.10	11.35	12	41448	415	79702513
Drug intolerance	35.89	11.35	51	41409	264068	79438860
Analgesic therapy	35.83	11.35	15	41445	994	79701934
Therapeutic product effect decreased	34.84	11.35	21	41439	163842	79539086
End stage renal disease	34.56	11.35	37	41423	12183	79690745
Hypochromasia	33.92	11.35	13	41447	683	79702245
Tendon calcification	33.47	11.35	9	41451	147	79702781
Drug therapy	33.31	11.35	15	41445	1186	79701742
Peripheral arterial occlusive disease	32.63	11.35	30	41430	8228	79694700
Dialysis	32.61	11.35	44	41416	18418	79684510
Hypervitaminosis D	31.88	11.35	8	41452	98	79702830
Iron deficiency	31.44	11.35	33	41427	10621	79692307
Hypoparathyroidism	31.37	11.35	14	41446	1084	79701844
Febrile neutropenia	30.99	11.35	45	41415	230954	79471974
Anaemia	30.72	11.35	360	41100	444655	79258273
Proteinuria	30.45	11.35	58	41402	32444	79670484
Suicide attempt	29.63	11.35	4	41456	82928	79620000
Left ventricular enlargement	29.57	11.35	12	41448	734	79702194
Sleep disorder therapy	29.07	11.35	13	41447	1011	79701917
Pericarditis	29.06	11.35	9	41451	104227	79598701
Dry mouth	28.84	11.35	106	41354	87913	79615015
Hypertensive heart disease	28.70	11.35	21	41439	4185	79698743
Nephrectomy	27.94	11.35	16	41444	2099	79700829
Narrow anterior chamber angle	27.59	11.35	8	41452	174	79702754
Nausea	27.56	11.35	671	40789	956525	78746403
Rash	27.49	11.35	182	41278	578176	79124752
Left atrial enlargement	27.07	11.35	13	41447	1190	79701738
Anti-erythropoietin antibody positive	26.61	11.35	11	41449	706	79702222
Shunt infection	26.39	11.35	8	41452	204	79702724
Hypersensitivity	26.35	11.35	61	41399	262178	79440750
Acute myocardial infarction	26.28	11.35	94	41366	76942	79625986
Pain	26.18	11.35	237	41223	703565	78999363
Product use issue	26.11	11.35	43	41417	209779	79493149
Lung diffusion test decreased	26.02	11.35	13	41447	1297	79701631
Cardiac arrest	25.52	11.35	165	41295	171931	79530997
Parathyroid tumour benign	25.20	11.35	11	41449	808	79702120
Hypophosphatasia	25.11	11.35	6	41454	59	79702869
Fungal peritonitis	25.10	11.35	12	41448	1088	79701840
Peritoneal dialysis	24.73	11.35	11	41449	845	79702083
Carotid arteriosclerosis	24.58	11.35	16	41444	2640	79700288
Diabetic foot	24.48	11.35	18	41442	3614	79699314
Pulmonary renal syndrome	24.36	11.35	10	41450	630	79702298
Suicidal ideation	24.35	11.35	5	41455	76335	79626593
Helicobacter infection	23.44	11.35	4	41456	69700	79633228
Azotaemia	23.30	11.35	25	41435	8251	79694677
Urosepsis	23.25	11.35	46	41414	26449	79676479
Joint contracture	22.86	11.35	15	41445	2509	79700419
Fatigue	22.60	11.35	344	41116	929383	78773545
Unresponsive to stimuli	22.49	11.35	72	41388	55716	79647212
Paraesthesia oral	22.30	11.35	39	41421	20432	79682496
Myasthenic syndrome	21.73	11.35	10	41450	832	79702096
Intentional product use issue	21.02	11.35	29	41431	152083	79550845
Blood erythropoietin decreased	20.47	11.35	4	41456	13	79702915
Mucosal inflammation	20.23	11.35	7	41453	75573	79627355
Haemoglobin decreased	20.15	11.35	190	41270	221929	79480999
Irritable bowel syndrome	20.01	11.35	4	41456	62237	79640691
Renal cyst	20.01	11.35	31	41429	14701	79688227
Psoriatic arthropathy	19.58	11.35	8	41452	77991	79624937
Blister	19.47	11.35	20	41440	119456	79583472
Hepatic cyst infection	19.19	11.35	6	41454	170	79702758
Blood potassium increased	19.01	11.35	45	41415	29230	79673698
Arteriovenous fistula site infection	18.99	11.35	6	41454	176	79702752
Fibromyalgia	18.96	11.35	5	41455	64335	79638593
Renal transplant failure	18.92	11.35	12	41448	1895	79701033
Arteriovenous fistula occlusion	18.91	11.35	8	41452	544	79702384
Arteriovenous fistula thrombosis	18.65	11.35	8	41452	563	79702365
High density lipoprotein decreased	18.56	11.35	17	41443	4638	79698290
Cerebral calcification	18.53	11.35	6	41454	191	79702737
Neutropenia	18.35	11.35	82	41378	287628	79415300
Nasopharyngitis	18.29	11.35	69	41391	253812	79449116
Hypertension	18.25	11.35	257	41203	330735	79372193
Serum ferritin increased	18.20	11.35	24	41436	9823	79693105
Bronchiolitis	18.09	11.35	16	41444	4172	79698756
Acute kidney injury	17.98	11.35	374	41086	519030	79183898
Polyhydramnios	17.50	11.35	11	41449	1709	79701219
Musculoskeletal stiffness	17.34	11.35	41	41419	174967	79527961
Interstitial granulomatous dermatitis	17.31	11.35	6	41454	236	79702692
Wound	17.24	11.35	21	41439	116158	79586770
Metabolic alkalosis	17.14	11.35	16	41444	4473	79698455
Peripheral swelling	17.09	11.35	77	41383	269540	79433388
Potentiating drug interaction	17.09	11.35	22	41438	8797	79694131
Pulmonary calcification	17.09	11.35	7	41453	439	79702489
Blood chloride increased	17.09	11.35	17	41443	5139	79697789
Nephrogenic anaemia	17.04	11.35	15	41445	3887	79699041
Hyperparathyroidism primary	16.83	11.35	7	41453	456	79702472
Blood alkaline phosphatase decreased	16.82	11.35	11	41449	1829	79701099
Injection site pain	16.72	11.35	26	41434	129812	79573116
Vascular parkinsonism	16.63	11.35	5	41455	124	79702804
Granuloma	16.55	11.35	21	41439	8276	79694652
Electrolyte imbalance	16.42	11.35	44	41416	30837	79672091
Cognitive disorder	16.25	11.35	8	41452	69918	79633010
Haematocrit decreased	16.18	11.35	69	41391	61243	79641685
Gastrointestinal haemorrhage	15.79	11.35	131	41329	147588	79555340
Arthritis	15.77	11.35	22	41438	114858	79588070
Plasma cell myeloma	15.68	11.35	62	41398	53197	79649731
Asthma	15.61	11.35	29	41431	135066	79567862
Encapsulating peritoneal sclerosis	15.60	11.35	8	41452	843	79702085
Lens dislocation	15.56	11.35	5	41455	155	79702773
Bone deformity	15.12	11.35	6	41454	346	79702582
Abdominal discomfort	15.07	11.35	73	41387	250654	79452274
Bloody peritoneal effluent	14.99	11.35	5	41455	175	79702753
Refractory cytopenia with unilineage dysplasia	14.97	11.35	8	41452	917	79702011
Obstruction	14.91	11.35	15	41445	4595	79698333
Urticaria	14.90	11.35	48	41412	185153	79517775
Stomatitis	14.84	11.35	34	41426	146723	79556205
Injection site reaction	14.79	11.35	5	41455	54780	79648148
Coagulation test abnormal	14.69	11.35	9	41451	1336	79701592
Hypocalcaemic seizure	14.46	11.35	4	41456	73	79702855
Alveolar bone resorption	14.41	11.35	4	41456	74	79702854
Complications of transplanted kidney	14.13	11.35	17	41443	6349	79696579
Coma	14.09	11.35	19	41441	100630	79602298
Drug reaction with eosinophilia and systemic symptoms	13.98	11.35	8	41452	64236	79638692
Pyelonephritis	13.96	11.35	32	41428	20356	79682572
Anti-erythropoietin antibody	13.86	11.35	3	41457	18	79702910
Dialysis hypotension	13.84	11.35	4	41456	86	79702842
Weight increased	13.80	11.35	86	41374	277300	79425628
Gangrene	13.80	11.35	20	41440	8944	79693984
Osteoarthritis	13.79	11.35	15	41445	87294	79615634
Blood iron decreased	13.79	11.35	27	41433	15407	79687521
Myopathy	13.78	11.35	32	41428	20531	79682397
Low turnover osteopathy	13.74	11.35	10	41450	1976	79700952
Graft thrombosis	13.70	11.35	6	41454	444	79702484
Night sweats	13.64	11.35	5	41455	52090	79650838
Sedation	13.56	11.35	5	41455	51890	79651038
Hepatocellular injury	13.46	11.35	4	41456	47589	79655339
Zoonosis	13.34	11.35	3	41457	22	79702906
Nephrolithiasis	13.32	11.35	59	41401	53232	79649696
Bacterial infection	13.18	11.35	41	41419	31239	79671689
Cardio-respiratory arrest	13.11	11.35	99	41361	108411	79594517
Blood 1,25-dihydroxycholecalciferol decreased	13.11	11.35	3	41457	24	79702904
Fanconi syndrome acquired	13.07	11.35	11	41449	2683	79700245
Transplant failure	13.03	11.35	14	41446	4627	79698301
Electrocardiogram T wave inversion	13.01	11.35	15	41445	5357	79697571
Oxygen saturation decreased	12.96	11.35	30	41430	129017	79573911
Urine protein/creatinine ratio increased	12.83	11.35	8	41452	1226	79701702
Lumbar vertebral fracture	12.80	11.35	17	41443	7005	79695923
Diabetes mellitus	12.76	11.35	77	41383	78313	79624615
Staphylococcal infection	12.70	11.35	62	41398	58233	79644695
Bone pain	12.66	11.35	60	41400	55682	79647246
Therapeutic product effect incomplete	12.63	11.35	35	41425	141610	79561318
Bone metabolism biochemical marker increased	12.60	11.35	3	41457	29	79702899
Malignant neoplasm progression	12.58	11.35	33	41427	135957	79566971
Lymphocyte count decreased	12.31	11.35	53	41407	47236	79655692
Cardiac valve disease	12.20	11.35	15	41445	5726	79697202
Haemodialysis complication	12.15	11.35	5	41455	317	79702611
Blood 1,25-dihydroxycholecalciferol increased	12.09	11.35	3	41457	35	79702893
Depression	11.96	11.35	65	41395	216725	79486203
Neutrophil count decreased	11.92	11.35	19	41441	93940	79608988
Peritoneal cloudy effluent	11.90	11.35	5	41455	334	79702594
Diffuse alopecia	11.90	11.35	7	41453	966	79701962
Impaired healing	11.82	11.35	17	41443	87638	79615290
Growth retardation	11.70	11.35	9	41451	1934	79700994
Fibrosis	11.49	11.35	14	41446	5295	79697633
Disease progression	11.47	11.35	53	41407	184309	79518619
Lower respiratory tract infection	11.46	11.35	32	41428	129188	79573740
Infarction	11.44	11.35	13	41447	4569	79698359
Overdose	11.44	11.35	53	41407	184153	79518775
Blood parathyroid hormone abnormal	11.42	11.35	5	41455	370	79702558
Breast induration	11.39	11.35	3	41457	45	79702883

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A11CC04	ALIMENTARY TRACT AND METABOLISM VITAMINS VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO Vitamin D and analogues
ATC	D05AX03	DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR TOPICAL USE Other antipsoriatics for topical use
FDA CS	M0004229	Cholecalciferol
MeSH PA	D050071	Bone Density Conservation Agents
MeSH PA	D002120	Calcium Channel Agonists
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018977	Micronutrients
MeSH PA	D014662	Vasoconstrictor Agents
MeSH PA	D014815	Vitamins
FDA EPC	N0000175908	Vitamin D3 Analog
CHEBI has role	CHEBI:24621	hormones
CHEBI has role	CHEBI:25212	metabolites
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38807	calcium channel agonists
CHEBI has role	CHEBI:38808	calcium channel modulators
CHEBI has role	CHEBI:50646	antiosteoporotic
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:50748	antipsoriatic drug
CHEBI has role	CHEBI:50846	Immunologic factor
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypophosphatemia	indication	4996001
Hypocalcemia	indication	5291005
Renal osteodystrophy	indication	16726004	DOID:13068
Hypoparathyroidism	indication	36976004	DOID:11199
Plaque psoriasis	indication	200965009
Hyperparathyroidism Secondary to Chronic Renal Failure	indication
Hypocalcemia from End-Stage Renal Disease with Dialysis	indication
Neonatal hypocalcemic tetany	off-label use	18442000
Vitamin D deficiency	off-label use	34713006
Rickets	off-label use	41345002	DOID:10609
Familial x-linked hypophosphatemic vitamin D refractory rickets	off-label use	82236004
Vitamin D Dependent Rickets	off-label use
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Hypervitaminosis D	contraindication	27712000	DOID:9971
Sarcoidosis	contraindication	31541009	DOID:11335
Hypercalcemia	contraindication	66931009	DOID:12678
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160
Hypercalcemia associated with Sarcoidosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
3MCG/GM	VECTICAL	GALDERMA LABS LP	N022087	Jan. 23, 2009	RX	OINTMENT	TOPICAL	July 17, 2023	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Vitamin D3 receptor	Nuclear hormone receptor	P11473	VDR_HUMAN	AGONIST	EC50	8.40	WOMBAT-PK	CHEMBL
Vitamin D 25-hydroxylase	Enzyme	Q6VVX0	CP2R1_HUMAN				WOMBAT-PK
Vitamin D-binding protein	Secreted	P02774	VTDB_HUMAN		Kd	7.62	CHEMBL
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	Enzyme	O15528	CP27B_HUMAN				WOMBAT-PK
Vitamin D3 receptor	Transcription factor		VDR_RAT		Ki	10.30	CHEMBL
Vitamin D3 receptor	Transcription factor		VDR_CHICK		Ki	10.60	CHEMBL
Vitamin D3 receptor	Transcription factor		VDR_BOVIN		EC50	10.30	CHEMBL
Vitamin D3 receptor	Nuclear hormone receptor		VDR_PIG		Kd	10.15	CHEMBL
Vitamin D3 receptor A	Nuclear hormone receptor		VDRA_DANRE		EC50	8.26	CHEMBL
Vitamin D3 receptor	Nuclear hormone receptor		VDR_MOUSE		EC50	7	CHEMBL

External reference:

ID	Source
4017800	VUID
N0000146161	NUI
D00129	KEGG_DRUG
152323	RXNORM
C0006674	UMLSCUI
CHEBI:17823	CHEBI
VDX	PDB_CHEM_ID
CHEMBL846	ChEMBL_ID
D002117	MESH_DESCRIPTOR_UI
DB00136	DRUGBANK_ID
5280453	PUBCHEM_CID
C118756	MESH_SUPPLEMENTAL_RECORD_UI
4393	INN_ID
FXC9231JVH	UNII
1311	MMSL
42410	MMSL
4324	MMSL
d03126	MMSL
259333003	SNOMEDCT_US
68206008	SNOMEDCT_US
4017800	VANDF
4021906	VANDF
2779	IUPHAR_LIGAND_ID
001017	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0007	CAPSULE	0.25 ug	ORAL	ANDA	22 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0007	CAPSULE	0.25 ug	ORAL	ANDA	22 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3120	SOLUTION	1 ug	ORAL	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3120	SOLUTION	1 ug	ORAL	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3120	SOLUTION	1 ug	ORAL	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7352	CAPSULE, LIQUID FILLED	0.25 ug	ORAL	ANDA	26 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7352	CAPSULE, LIQUID FILLED	0.25 ug	ORAL	ANDA	26 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7353	CAPSULE, LIQUID FILLED	0.50 ug	ORAL	ANDA	26 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7353	CAPSULE, LIQUID FILLED	0.50 ug	ORAL	ANDA	26 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9728	INJECTION	1 ug	INTRAVENOUS	ANDA	24 sections
Vectical	HUMAN PRESCRIPTION DRUG LABEL	1	0299-2012	OINTMENT	3 ug	TOPICAL	NDA	26 sections
Vectical	HUMAN PRESCRIPTION DRUG LABEL	1	0299-2012	OINTMENT	3 ug	TOPICAL	NDA	26 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17478-831	INJECTION	1 ug	INTRAVENOUS	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17478-831	INJECTION	1 ug	INTRAVENOUS	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17478-931	INJECTION	1 ug	INTRAVENOUS	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17478-931	INJECTION	1 ug	INTRAVENOUS	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17478-932	INJECTION	2 ug	INTRAVENOUS	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17478-932	INJECTION	2 ug	INTRAVENOUS	ANDA	23 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0723	CAPSULE	0.25 ug	ORAL	ANDA	21 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	17856-3120	SOLUTION	1 ug	ORAL	ANDA	25 sections
CALCITRIOL	HUMAN PRESCRIPTION DRUG LABEL	1	23155-662	CAPSULE	0.25 ug	ORAL	ANDA	21 sections
CALCITRIOL	HUMAN PRESCRIPTION DRUG LABEL	1	23155-662	CAPSULE	0.25 ug	ORAL	ANDA	21 sections
CALCITRIOL	HUMAN PRESCRIPTION DRUG LABEL	1	23155-663	CAPSULE	0.50 ug	ORAL	ANDA	21 sections
CALCITRIOL	HUMAN PRESCRIPTION DRUG LABEL	1	23155-663	CAPSULE	0.50 ug	ORAL	ANDA	21 sections
Rocaltrol	HUMAN PRESCRIPTION DRUG LABEL	1	30698-143	CAPSULE, GELATIN COATED	0.25 ug	ORAL	NDA	24 sections
Rocaltrol	HUMAN PRESCRIPTION DRUG LABEL	1	30698-144	CAPSULE, GELATIN COATED	0.50 ug	ORAL	NDA	24 sections
Rocaltrol	HUMAN PRESCRIPTION DRUG LABEL	1	30698-911	SOLUTION	1 ug	ORAL	NDA	24 sections
Calcitriol	HUMAN PRESCRIPTION DRUG LABEL	1	43353-034	CAPSULE	0.25 ug	ORAL	ANDA	26 sections
CALCITRIOL	HUMAN PRESCRIPTION DRUG LABEL	1	43353-138	CAPSULE	0.25 ug	ORAL	NDA authorized generic	26 sections
Rocaltrol	HUMAN PRESCRIPTION DRUG LABEL	1	43353-633	CAPSULE, GELATIN COATED	0.25 ug	ORAL	NDA	22 sections